Delving into the Latest Updates on rSIFN-co with Synapse

Overview

Basic Info

Drug Type

Interferons

Synonyms

Crystalline recombinant interferon, Recombinant super compound interferon, Recombinant super interferon compound

+ [1]

Target

IFNLR1

Mechanism

IFNLR1 agonists(interferon lambda receptor 1 agonists)

Therapeutic Areas

NeoplasmsInfectious DiseasesDigestive System Disorders

Active Indication

Hepatitis B, ChronicSolid tumor

Inactive Indication

Advanced Malignant Solid NeoplasmColonic CancerHepatocellular Carcinoma+ [3]

Originator Organization

Sichuan Huiyang Life-Engineering Co. Ltd.

Active Organization

Sichuan Huiyang Life-Engineering Co. Ltd.

Inactive Organization-

Drug Highest PhasePhase 3

First Approval Date-

Regulation-

Login to view timeline

Gene Sequence

Sequence Code 8226

An International, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel, Phase II Pilot Study to Evaluate the Efficacy and Safety of Recombinant Super-compound Interferon (rSIFN-co) Among Healthy Subjects in Close Contact With Confirmed COVID-19 Case(s) and Subjects With Mild or Asymptomatic COVID-19

This is a phase II pilot, international, multicenter, randomized, double-blind, placebo-controlled study that aims to evaluate the safety and preliminary efficacy of rSIFN-co nasal spray in healthy subjects in close contact with confirmed COVID-19 case(s) as well as subjects with mild or asymptomatic COVID-19.

Start Date01 Jul 2022

Sponsor / Collaborator

Sichuan Huiyang Life-Engineering Co. Ltd.

NCT02464007 / Active, not recruitingPhase 1

A Phase 1 Study of rSIFN-co for Subjects With Advanced Solid Tumors Where Interferons Are Known to Have Demonstrated Antitumor Activity

In this EffTox dose escalation study, up to 3 dose levels will be tested. The optimal dose (OD) of rSIFN-co will be determined using the EffTox design. Additional subject cohorts will not be enrolled until all subjects at the current dose level complete 28 days without DLT. The optimal dose (OD) will be determined by evaluation of safety in each cohort and disease response by RECIST 1.1 at 8 weeks. Once the OD is determined, enrollment will continue until at least 9 subjects total are accrued at the OD. Pharmacokinetics of rSIFN-co will be conducted for all tested dose levels to characterize dose proportionality.

Start Date01 Jan 2016

Sponsor / Collaborator

Sichuan Huiyang Life-Engineering Co. Ltd.

[+1]

NCT02387307 / CompletedPhase 1

A Phase I Open-Label, Non-Randomized, Dose-Escalation Study of rSIFN-co in Subjects With Advanced Solid Tumors and With an Expansion Cohort at Recommended Dose (RD) in Subjects With Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Melanoma, Hepatocellular Carcinoma or Colon Cancer

This is a multicenter, open-label, phase I study of rSIFN-co (3 times a week via subcutaneous injection for 21 days, with 1 week of washout per cycle).

Start Date01 Jul 2013

Sponsor / Collaborator

Sichuan Huiyang Life-Engineering Co. Ltd.

100 Clinical Results associated with rSIFN-co

Login to view more data

100 Translational Medicine associated with rSIFN-co

Login to view more data

100 Patents (Medical) associated with rSIFN-co

Login to view more data

217

Literatures (Medical) associated with rSIFN-co

01 Sep 2024·Brazilian Journal of Otorhinolaryngology

Interferon alpha-2b treatment for exophytic nasal papillomas and human papillomavirus infection

Article

Author: Anastasia, Kozlova ; Andrey, Boyko ; Pavel, Tregub ; Vladimir, Petrovskii ; Irada, Ibrahimli ; Inga, Popova ; Timur, Shadyev ; Irina, Apollonova ; Svetlana, Starostina ; Tatiana, Degtyarevskaya

OBJECTIVESExophytic Sinonasal Papilloma (ESP) is a benign tumor of the sinonasal tract. Complete surgical excision by endoscopic surgery is the treatment of choice. However, a high recurrence rate (36% at 5-year follow-up) is associated with this method, which may indicate the presence of microorganisms such as Human Papillomavirus (HPV). It is important to note that the standard treatment for ESP does not include antiviral drugs. In our study, we are testing the effectiveness of an interferon-containing drug in reducing recurrence and postoperative reactions in patients with ESP.METHODSWe included 78 patients aged 23-83 years with a confirmed diagnosis of ESP by rhinoscopy and nasal endoscopy and a positive PCR test for HPV in nasal scrapings. To compare the results, we divided the patients into main and control groups. The main group received recombinant human interferon after surgery, while the control group did not receive the drug. We performed a statistical analysis to compare the proportion of patients without reactive manifestations at different stages of the postoperative period, as well as to compare the proportion of patients with recurrent ESP at certain stages of observation.RESULTSThe introduction of recombinant human interferon accelerated the resolution of postoperative reactions and promoted the healing of the nasal mucosa after surgical removal of the ESP. We also found a statistically significant association between treatment with recombinant interferon and a reduction in the recurrence rate of ESP.CONCLUSIONAccording to the results of the study, it was found that in the main group of patients who received rhIFN-α2b (recombinant human Interferon alpha 2b) in the postoperative period, the frequency of relapses of ESP and the time of postoperative recovery were significantly lower than in patients in the control group who did not take the drug.LEVEL OF EVIDENCECohort Study.

01 Jul 2023·Antiviral Research

Recombinant porcine interferon cocktail delays the onset and lessens the severity of African swine fever

Article

Author: Fan, Wenhui ; Yin, Hongyan ; Zhang, He ; Shang, Yingli ; Jiao, Pengtao ; Wang, Shuchao ; Sun, Lei ; Liu, Wenjun ; Zhu, Hongfei ; Hu, Rongliang

African swine fever (ASF) is a highly contagious and deadly disease that affects domestic and wild pigs. No commercial vaccine or antiviral is currently available against ASF. The control of ASF primarily relies on implementing effective biosecurity measures during the breeding process. Here, we evaluated the preventive and therapeutic potential of the interferon (IFN) cocktail (a mixture of recombinant porcine IFN α and γ) on ASF. The IFN cocktail treatment delayed the onset of ASF symptoms and ASF virus (ASFV) replication for approximately one week. However, IFN cocktail treatment could not prevent the death of the pigs. Further analysis showed that IFN cocktail treatment increased the expression of multiple IFN-stimulated genes (ISGs) in porcine peripheral blood mononuclear cells in vivo and in vitro. Additionally, IFN cocktail modulated the expression of pro- and anti-inflammatory cytokines and reduced tissue injury in the ASFV-infected pigs. Collectively, the results suggest that the IFN cocktail restricts the progression of acute ASF by inducing high levels of ISGs, contributing to the pre-establishment of antiviral status, and modulating the balance of pro- and anti-inflammatory mediators to lessen cytokine storm-mediated tissue damage.

15 Oct 2022·Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics

[Clinical features of children and their family members with family clusters of SARS-CoV-2 Omicron variant infection in Shanghai, China: an analysis of 380 cases].

Article

Author: Li, Miao-Chen ; Jiang, Qin ; Chen, Juan-Juan ; Zhang, Kun ; Guo, Zhi ; Zhang, Jin-Ping ; Fan, Sai-Nan ; Guo, Miao-Miao ; Zheng, Fang ; Wu, Zhi-Min ; Hui, Lei ; Bian, Xiang-Li

OBJECTIVESTo study the clinical features and prognosis of children and their family members with family clusters of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant infection under the admission mode of parent-child ward.METHODSA retrospective analysis was performed on the medical data of 190 children and 190 family members with SARS-CoV-2 Omicron variant infection who were admitted to Shanghai Sixth People's Hospital, the designated hospital for coronavirus disease 2019 (COVID-19), April 8 to May 10, 2022.RESULTSBoth the child and adult groups were mainly mild COVID-19, and the proportion of mild cases in the child group was higher than that in the adult group (P<0.05). Respiratory symptoms were the main clinical manifestations in both groups. Compared with the adult group, the child group had higher incidence rates of fever, abdominal pain, diarrhea, and wheezing (P<0.05) and lower incidence rates of nasal obstruction, runny nose, cough, dry throat, throat itching, and throat pain (P<0.05). Compared with the child group, the adult group had higher rates of use of Chinese patent drugs, traditional Chinese medicine decoction, recombinant interferon spray, cough-relieving and phlegm-eliminating drugs, and nirmatrelvir/ritonavir tablets (P<0.05). Compared with the adult group, the child group had a lower vaccination rate of SARS-CoV-2 vaccine (30.5% vs 71.1%, P<0.001) and a shorter duration of positive SARS-CoV-2 nucleic acid (P<0.05). The patients with mild COVID-19 had a shorter duration of positive SARS-CoV-2 nucleic acid than those with common COVID-19 in both groups (P<0.05). The patients with underlying diseases had a longer duration of positive SARS-CoV-2 nucleic acid than those without such diseases in both groups (P<0.05).CONCLUSIONSBoth children and adults with family clusters of SARS-CoV-2 Omicron variant infection manifest mainly mild COVID-19. Despite lower vaccination rate of SARS-CoV-2 vaccine in children, they have rapid disease recovery, with a shorter duration of positive SARS-CoV-2 nucleic acid than adults, under the admission mode of parent-child ward.

100 Deals associated with rSIFN-co

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB15752

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hepatitis B, Chronic	Phase 3	CN	Sichuan Huiyang Life-Engineering Co. Ltd.	17 Sep 2011
Solid tumor	Phase 1	US	Sichuan Huiyang Life-Engineering Co. Ltd.	01 Jan 2016
Advanced Malignant Solid Neoplasm	Discovery	SG	Sichuan Huiyang Life-Engineering Co. Ltd.	01 Jul 2013
Colonic Cancer	Discovery	SG	Sichuan Huiyang Life-Engineering Co. Ltd.	01 Jul 2013
Hepatocellular Carcinoma	Discovery	SG	Sichuan Huiyang Life-Engineering Co. Ltd.	01 Jul 2013
Melanoma	Discovery	SG	Sichuan Huiyang Life-Engineering Co. Ltd.	01 Jul 2013
Non-Small Cell Lung Cancer	Discovery	SG	Sichuan Huiyang Life-Engineering Co. Ltd.	01 Jul 2013
Renal Cell Carcinoma	Discovery	SG	Sichuan Huiyang Life-Engineering Co. Ltd.	01 Jul 2013